Last updated: February 16, 2026
What is the drug with NDC 54738-0985?
NDC 54738-0985 references Tucatinib (brand name: Tukysa), a targeted therapy for HER2-positive breast cancer. It is an oral tyrosine kinase inhibitor approved by the FDA in April 2020 for adult patients with unresectable or metastatic HER2-positive breast cancer, specifically in combination with trastuzumab and capecitabine.
What is the current market landscape for Tucatinib?
Market size and revenue
Tucatinib's revenue depends on market penetration in HER2-positive breast cancer treatment. In 2022, HER2-targeted therapies generated approximately $5 billion globally, with growth driven by expanding indications and combination therapies. Tucatinib, being a recently approved drug with a specialized niche, commands a smaller share within this market.
Competition and market share
Primary competitors include:
- Trastuzumab (Herceptin)
- Pertuzumab (Perjeta)
- Ado-trastuzumab emtansine (Kadcyla)
- Lapatinib (Tykerb)
- Neratinib (Nerlynx)
Tucatinib's unique position stems from its specificity for HER2 and its combination data demonstrating efficacy in brain metastases.
Adoption factors
- Regulatory approvals: Limited to certain indications, affecting initial sales.
- Pricing strategies: High-compliance medication with premium pricing, adjusted for market competition.
- Clinical data: Positive trial outcomes (HER2CLIMB) support broader use.
- Reimbursement landscape: Favorable in major markets due to established protocols for HER2-positive breast cancer.
What are the price projections for Tucatinib?
Current pricing
As of 2023, the list price for Tucatinib in the U.S. is approximately $10,000 per month per patient, based on dosing regimens of 300 mg twice daily. This price is comparable or slightly higher than similar oral kinase inhibitors, considering its targeted nature.
Short-term projections (2023-2025)
- Price stability: No significant upward price pressure anticipated due to market competition and payer negotiations.
- Pricing adjustments: Slight decreases may occur as generic competition emerges, although patent exclusivity extends until 2030.
- Reimbursement: Insurance coverage remains robust due to clinical efficacy data, enabling sustained revenue for the manufacturer.
Long-term projections (2026-2030)
- Market expansion: Potentially larger patient access as evidence broadens for second-line or earlier-line treatment.
- Price erosion: Possible 10-15% reduction in net prices due to biosimilar competition or generic entrants post patent expiry.
- Pricing trends: Anticipated to remain premium relative to less-specific TKIs, with gradual decreases tied to market dynamics.
Factors influencing price changes
| Factor |
Impact |
Timeline |
| Patent expiration |
Entry of generics, potential price reduction |
2030 |
| Competition from biosimilars |
Erosion of market share, pressure on pricing |
2028–2030 |
| Inclusion in treatment guidelines |
Increased adoption, stabilizing prices |
2023–2025 |
| Healthcare policy shifts |
Price controls, reimbursement policies |
2023–2030 |
What are the key market and pricing risks?
- Patent challenges threaten to introduce generic versions before 2030.
- Market saturation in HER2-positive therapy could limit price growth.
- Reimbursement constraints may restrict pricing flexibility.
- Clinical trial failures in broader indications could reduce expansion potential.
What are the strategic implications for stakeholders?
- Pharmaceutical developers should monitor patent status and biosimilar trajectories.
- Investors should consider Tucatinib’s projected market share growth in HER2-positive breast cancer.
- Healthcare providers will weigh the cost-benefit ratio, especially considering competing therapies.
Key takeaways
- Tucatinib is a targeted HER2 kinase inhibitor with an estimated monthly price of $10,000.
- Market growth hinges on expanding clinical indications and improved patient access.
- Competition and patent exclusivity shape its price trajectory, with possible decreases after 2028.
- Long-term viability depends on pharmacoeconomic positioning and regulatory developments.
FAQs
Q1: When are biosimilars or generics expected for Tucatinib?
A1: Patents extend until approximately 2030. Biosimilar competition could begin post-2030, with biosimilar approval processes potentially starting 5-7 years prior.
Q2: How does Tucatinib compare to other HER2-targeted therapies?
A2: It offers specificity for HER2 and demonstrates efficacy in brain metastases. Its oral administration and combination potential differentiate it from IV therapies like trastuzumab.
Q3: What factors could accelerate market adoption?
A3: Positive clinical trial results, inclusion in treatment guidelines, and payer reimbursement policies.
Q4: What are the main barriers to price increases?
A4: Competition, biosimilar entry, and policy-driven price controls.
Q5: How does the high cost affect access?
A5: Cost may restrict use in certain systems or patient populations, but reimbursement and clinical value support sustained use in approved indications.
References
[1] IQVIA. "Her2-positive breast cancer market report," 2022.
[2] FDA. "Tucatinib (Tukysa) approval letter," April 2020.
[3] EvaluatePharma. "Global oncology drug market, 2022."
[4] American Society of Clinical Oncology. "HER2CLIMB trial results," 2021.
[5] Medicare and Medicaid Services. "Reimbursement guidelines for targeted therapies," 2022.
